01 Nov
2023
03:00 E.S.T.

Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca

Read more

31 Oct
2023
16:30 E.S.T.

Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Read more

24 Oct
2023
16:30 E.S.T.

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress

Read more

12 Oct
2023
04:30 E.S.T.

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)

Read more

27 Sep
2023
16:30 E.S.T.

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Read more

07 Aug
2023
09:41 E.S.T.

Cellectis Provides Full Report for Second Quarter 2023 Financial Results

Read more

03 Aug
2023
12:52 E.S.T.

Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023

Read more

26 Jul
2023
09:47 E.S.T.

Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023

Read more

12 Jul
2023
10:29 E.S.T.

Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors

Read more

28 Jun
2023
10:33 E.S.T.

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023

Read more